Tizanidine
Severe
Database
Clinical effect not specified
Source: DDInter
Drug reference
nesiritide
Synthetic BNP agonist
Synthetic BNP agonist
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
1 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactions
- TizanidineSevereDatabaseDDInter
Mechanism
Not yet extracted
Indications
heart failureacute decompensated heart failure (with dyspnea with minimal activity or at rest)acutely decompensated heart failure (previously approved in US, manufacturing discontinued in 2018)i.v. use to relieve dyspnoea and other symptoms in refractory CHF
Pharmacokinetics
Duration
Clearance occurs via internalization and degradation mediated by NPCR, and metabolism by extracellular proteases.
Half-life
distribution t1/2 of 2 min, terminal t1/2 of 18 min
Contraindications
- no long-term benefits in CHF
Side effects
Serious
- hypotension
- adverse renal effects (not demonstrated to worsen renal function in heart failure patients)
- increased risk for renal failure and death
Drug interactions
11 additional low-confidence interactions hidden — those rows lack a documented mechanism or management plan in our sources.
Related guidelines
Ask House about nesiritide
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: KD Tripathi 7e, Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team